In November 2004, the FDA issued a final rule requiring HCT/P establishments to operate in accordance with Current Good Tissue Practice (CGTP) for the collection, donor screening, donor testing, processing, storage, labeling, packaging and distribution of HCT/Ps to prevent the introduction, transmission and spread of communicable diseases. The core CGTP requirements cover facilities, environmental controls, equipment, supplies and reagents, recovery, processing and processing controls, labeling controls, storage, and distribution (including receipt and predistribution shipment). The regulations for CGTPs are found in 21 CFR 1271 Subpart D; FDA recommendations for compliance with the regulations also are available.
AABB Accepting Applications for 2026 Future Leader Scholarship Awards Program
March 03, 2026
FDA Seeks Comment on BPD, HCT/P Deviation Reporting
February 25, 2026
FDA Issues Draft Guidance Establishing Framework for Individualized Gene Therapies
February 25, 2026